Trial Profile
A phase III trial of tipapkinogene sovacivec in patients with cervical intraepithelial neoplasia caused by human papilloma virus infection.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2007
Price :
$35
*
At a glance
- Drugs Tipapkinogene sovacivec (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Registrational; Therapeutic Use
- 22 Mar 2007 New trial record.